REG - AOTI, Inc. - Appointment of Joint Corporate Broker

AotiAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251006:nRSF1093Ca&default-theme=true

RNS Number : 1093C  AOTI, Inc.  06 October 2025

6 October 2025

 

 

AOTI, INC. (the "Company" or "Group" or "AOTI")

 

Appointment of Joint Corporate Broker

 

AOTI, INC., a medical technology group focused on the durable healing of
wounds and prevention of amputations, is pleased to announce the appointment
of Panmure Liberum Limited as Joint Corporate Broker, working alongside Peel
Hunt LLP, the Company's Nominated Adviser and existing corporate broker.

 

END

 

 AOTI, INC.

 Dr. Mike Griffiths, Chief Executive Officer         +44 (0)20 3727 1000

 Jayesh Pankhania, Chief Financial Officer           ir@aotinc.net (mailto:ir@aotinc.net)

 Peel Hunt LLP (Nominated Adviser and Joint Broker)

 Dr. Christopher Golden, James Steel                 +44 (0)20 7418 8900

 Panmure Liberum Limited (Joint Broker)              +44 (0)20 3100 2000

 Emma Earl, Will Goode, Mark Rogers

 Rupert Dearden

 FTI Consulting (Financial PR & IR)                  +44 (0)20 3727 1000

 Ben Atwell, Simon Conway,                           AOTI@fitconsulting.com (mailto:AOTI@fitconsulting.com)

 Natalie Garland-Collins

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and
Galway, Ireland, providing innovative solutions to resolve severe and chronic
wounds worldwide. Its products reduce healthcare costs and improve the quality
of life for patients with these debilitating conditions. The Company's
patented non-invasive Topical Wound Oxygen (TWO(2)(®)) therapy has
demonstrated in differentiating, robust, double-blinded randomized controlled
trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the
recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88
per cent reduction in hospitalizations and 71 per cent reduction in
amputations over 12 months. TWO(2)(®) therapy can be administered by the
patient at home, improving access to care and enhancing treatment compliance.
TWO(2)(®) therapy has received regulatory clearance from the US (FDA), Europe
(CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products
Administration, Australia (TGA) and in Saudi Arabia. TWO(2)(®) therapy has
also recently received positive coverage recommendations from the Federal
Joint Committee (G-BA) in Germany and National Institute for Health and Care
Excellence (NICE) in the United Kingdom. Also see www.aotinc.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPUPGUCUUPAGAA